Pediatrix Medical Group

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 19 Feb 2026, plus the 10-Q filed 4 Aug 2026 and 5 later 8-Ks.

• Sales have barely grown: 2.0% a year.

Whether the price already reflects the risks is what the deep dive is for.

• Our use of artificial intelligence (“AI”) technologies may expose us to additional legal, regulatory, operational, and competitive risks.

  Could happen

  Some of our information systems that support our day-to-day operations, ongoing clinical initiatives and business analyses increasingly utilize AI, including to assist with clinical documentation. AI technologies are highly complex and rapidly evolving, and their use presents risks, challenges and the potential for unintended consequences, including errors, bias, system failures, or limitations in performance, which could affect their adoption or effectiveness and, in turn, our operations and business. At the same time, our ability to remain competitive may depend in part on our ability to effectively develop, implement and utilize AI technologies. If we are unable to keep pace with technological developments or the adoption of AI by competitors, or if competitors are able to achieve greater operational efficiencies, cost savings, or service enhancements through their use of AI, our competitive position, operating results, or growth prospects could be adversely affected.

  Read moreShow less

• Expanding eligibility of GHC Programs could adversely affect our reimbursement.

  Could happen

  In general, payments received from GHC Programs are substantially less than payments received from private healthcare insurance programs (managed care and other third-party payors). A shift in the mix of our payors from private healthcare insurance programs to government payors may result in an increase in our estimated provision for contractual adjustments and uncollectibles and a corresponding decrease in our net revenue, as well as a significant reduction in our average reimbursement rates. Further, the Congressional Budget Office has estimated that the One Big Beautiful Bill Act will cut federal spending on Medicaid and CHIP benefits by $1 trillion, due in part to eliminating at least 10.5 million people from the programs by 2034. If Congress does not act to extend CHIP beyond 2027, or if Congress extends CHIP but substantially alters the current program, we could be adversely affected if children in states where we do business lose Medicaid coverage or payments for services furnished to these children are delayed or reduced.

  Read moreShow less

• Our use of artificial intelligence (“AI”) technologies may expose us to additional legal, regulatory, operational, and competitive risks.

  Could happen

  Compliance with current or future AI-related laws and regulations, or changes in their interpretation, could require us to modify our information systems, limit or discontinue certain uses of AI, or incur additional costs to ensure compliance. We may not be able to anticipate or respond effectively to these developments, and failure to comply could result in legal or regulatory actions, fines, penalties, or reputational harm. The costs associated with compliance, system modifications, or potential disruptions to our operations could be significant and could have a material adverse effect on our business, financial condition, and results of operations.

  Read moreShow less

• The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws, rules or regulations.

  Could happen

  We may in the future become the subject of regulatory or other investigations, audits or proceedings, and our interpretations of applicable laws, rules and regulations may be challenged, which could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. For example, in some states, we are dependent on our relationship with affiliated physician practices, which we do not own, to provide physician and other clinical services, and our business would be adversely affected if those relationships were disrupted or if our arrangements with our providers are found to violate state laws prohibiting the corporate practice of medicine or fee splitting, or if our contractual relationships with such entities cease to continue. Our contracts include management services agreements among other agreements with such affiliated physician practices, to which these practices reserve exclusive control and responsibility for all aspects of the practice of medicine and delivery of medical services. Recent state legislative activity has reflected growing scrutiny of the corporate practice of medicine, with a number of states proposing or enacting laws to expand existing prohibitions, enhance disclosure and reporting obligations, and broaden enforcement authority over management and ownership arrangements between healthcare providers and non-clinical entities. While we seek to substantially comply with the applicable state prohibitions on the corporate practice of medicine and fee splitting, these laws could impact our business operations, and state officials who administer these laws or other third parties may successfully challenge our contractual arrangements, which could subject us to civil and criminal penalties and require us to restructure our relationships with providers to comply with these statutes, which could have a material adverse effect on our business, financial condition, and operations. Additionally, state corporate practice of medicine doctrines often impose penalties on physicians themselves for aiding the corporate practice of medicine, which could impact physicians participating with our affiliated physician practices. See Item 1. Business—“Government Regulation—Fee Splitting; Corporate Practice of Medicine.”

  Read moreShow less

• Potential healthcare reform efforts may have a significant effect on our business.

  Could happen

  In addition to the ACA, there could be changes to other GHC Programs, such as a change to the Medicaid program design or Medicaid coverage and reimbursement rates set forth under federal or state law. For example, on July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act, which reforms the Medicaid program by eliminating certain financial incentives for states that have expanded their Medicaid programs under the ACA, imposing work requirements on certain adult beneficiaries, and requiring states to increase patient cost-sharing amounts for certain services. These reforms to the Medicaid program could have a material impact on our business.

  Read moreShow less